|
1.
|
|
14 p, 1.6 MB |
Characteristics of subjective cognitive decline associated with amyloid positivity
/
Janssen, Olin (Maastricht University. School for Mental Health and Neuroscience) ;
Jansen, W.J. (Maastricht University. School for Mental Health and Neuroscience) ;
Vos, S.J.B. (Maastricht University. School for Mental Health and Neuroscience) ;
Boada, Mercè (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Parnetti, Lucilla (Section of Neurology. Center for Memory Disturbances - Lab. of Clinical Neurochemistry. Department of Medicine and Surgery. University of Perugia) ;
Gabryelewicz, T. (Department of Neurodegenerative Disorders. Mossakowski Medical Research Centre. Polish Academy of Sciences) ;
Fladby, T. (Department of Neurology. Akershus University Hospital) ;
Molinuevo, José Luis (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Villeneuve, S. (Centre for Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre) ;
Hort, J. (International Clinical Research Center. St. Anne's University Hospital) ;
Epelbaum, S. (Inserm Sorbonne Université. Inria. Aramis project-team. Paris Brain Institute - Institut du Cerveau (ICM)) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Engelborghs, Sebastiaan (Vrije Universiteit Brussel. (VUB) Brussels. and University of Antwerp) ;
van der Flier, W.M. (Alzheimer Center Amsterdam. Department of Neurology. Amsterdam Neuroscience. Amsterdam UMC. Vrije Universiteit Amsterdam) ;
Landau, S. (Helen Wills Neuroscience Institute. University of California) ;
Popp, J. (Old Age Psychiatry. University Hospital of Lausanne) ;
Wallin, Anders (Institute of Neuroscience and Physiology. Sahlgrenska Academy at University of Gothenburg) ;
Scheltens, P. (Alzheimer Center Amsterdam. Department of Neurology. Amsterdam Neuroscience. Amsterdam UMC. Vrije Universiteit Amsterdam) ;
Rikkert, M.O. (Department of Geriatric Medicine. Radboud Alzheimer Center. Radboud University Medical Center) ;
Snyder, P.J. (Kingston. The University of Rhode Island) ;
Rowe, C. (Department of Molecular Imaging & Therapy. Austin Health) ;
Chételat, G.. (Institut National de la Santé et de la Recherche Médicale (Inserm)) ;
Ruíz, A. (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Marquié, M. (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Chipi, E. (Section of Neurology. Center for Memory Disturbances - Lab. of Clinical Neurochemistry. Department of Medicine and Surgery. University of Perugia) ;
Wolfsgruber, S. (Department of Neurodegenerative Diseases and Psychiatry. University Hospital Bonn) ;
Heneka, M. (Department of Neurodegenerative Diseases and Psychiatry. University Hospital Bonn) ;
Boecker, H. (Functional Neuroimaging Group. Department of Radiology. University Hospital Bonn) ;
Peters, O. (Charité - Universitätsmedizin Berlin) ;
Jarholm, J. (Department of Neurology. Akershus University Hospital) ;
Rami, L. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Tort-Merino, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Binette, A.P. (Centre for Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre) ;
Poirier, J. (Centre for Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre) ;
Rosa-Neto, P. (Centre for Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre) ;
Cerman, J. (International Clinical Research Center. St. Anne's University Hospital) ;
Dubois, B. (AP-HP. Hôpital de la Pitié Salpêtrière. Institute of Memory and Alzheimer's Disease (IM2A). Centre of excellence of neurodegenerative disease (CoEN). Department of Neurology) ;
Teichmann, M. (AP-HP. Hôpital de la Pitié Salpêtrière. Institute of Memory and Alzheimer's Disease (IM2A). Centre of excellence of neurodegenerative disease (CoEN). Department of Neurology) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau) ;
Sánchez-Saudinós, María Belén (Institut d'Investigació Biomèdica Sant Pau) ;
Ebenau, J. (Alzheimer Center Amsterdam. Department of Neurology. Amsterdam Neuroscience. Amsterdam UMC. Vrije Universiteit Amsterdam) ;
Pocnet, C. (Old Age Psychiatry. University Hospital of Lausanne) ;
Eckerström, M. (Institute of Neuroscience and Physiology. Sahlgrenska Academy at University of Gothenburg) ;
Thompson, L. (Kingston. The University of Rhode Island) ;
Villemagne, V. (Department of Psychiatry. University of Pittsburgh) ;
Buckley, R. (Brigham and Women's Hospital and Department of Neurology Massachusetts General Hospital. Harvard Medical School) ;
Burnham, S. (Section of Neurology. Center for Memory Disturbances - Lab. of Clinical Neurochemistry. Department of Medicine and Surgery. University of Perugia) ;
Delarue, M. (Institut National de la Sant. et de la Recherche M.dicale (Inserm)) ;
Freund-Levi, Yvonne (Department of Neurobiology. Care Sciences and Society. Karolinska Institutet) ;
Wallin, Å.K. (Department of Clinical Sciences Malmö. Clinical Memory Research Unit. Lund University) ;
Ramakers, I. (Maastricht University. School for Mental Health and Neuroscience) ;
Tsolaki, Magda (Memory and Dementia Center. 3rd Department of Neurology. "G Papanicolau. " General Hospital. Aristotle University of Thessaloniki) ;
Soininen, H. (Institute of Clinical Medicine. Neurology. University of Eastern Finland) ;
Hampel, H. (GRC no 21. Alzheimer Precision Medicine (AMP). AP-HP. Pitié-Salpêtrière Hospital. Sorbonne University) ;
Spiru, L. (Geriatrics- Gerontology and Old Age Psychiatry. Alzheimer Unit. Ana Aslan International Foundation - Memory Center and Longevity Medicine) ;
Tijms, B. (Maastricht University. School for Mental Health and Neuroscience) ;
Ossenkoppele, R. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Verhey, F.R.J. (Maastricht University. School for Mental Health and Neuroscience) ;
Jessen, F. (German Center For Neurodegenerative Diseases/Clinical Research. Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE). Zentrum für klinische Forschung/AG) ;
Visser, P.J. (Department of Neurobiology. Care Sciences and Society. Karolinska Institutet)
Introduction: The evidence for characteristics of persons with subjective cognitive decline (SCD) associated with amyloid positivity is limited. Methods: In 1640 persons with SCD from 20 Amyloid Biomarker Study cohort, we investigated the associations of SCD-specific characteristics (informant confirmation, domain-specific complaints, concerns, feelings of worse performance) demographics, setting, apolipoprotein E gene (APOE) ε4 carriership, and neuropsychiatric symptoms with amyloid positivity. [...]
2022 -  10.1002/alz.12512
Alzheimer's & Dementia, Vol. 18 Núm. 10 (october 2022) , p. 1832-1845
|
|
|
2.
|
|
15 p, 2.1 MB |
Sex-specific metabolic pathways were associated with alzheimer's disease (Ad) endophenotypes in the european medical information framework for ad multimodal biomarker discovery cohort
/
Xu, J. (King's College London) ;
Green, R. (King's College London) ;
Kim, M. (Steno Diabetes Center) ;
Lord, J. (King's College London) ;
Ebshiana, A. (King's College London) ;
Westwood, S. (Department of Psychiatry. University of Oxford) ;
Baird, Alison L (Department of Psychiatry. University of Oxford) ;
Nevado-Holgado, Alejo (Department of Psychiatry. University of Oxford) ;
Shi, L. (Department of Psychiatry. University of Oxford) ;
Hye, Abdul (King's College London) ;
Snowden, S. G. (King's College London) ;
Bos, Isabelle (Amsterdam UMC. University Medical Center) ;
Vos, S. J. B. (Maastricht University) ;
Vandenberghe, R. (Alzheimer Center. VU University Medical Center) ;
Teunissen, C. E. (Department of Radiology and Nuclear Medicine. VU University Medical Center) ;
Kate, M. T. (Department of Radiology and Nuclear Medicine. VU University Medical Center) ;
Scheltens, P. (Alzheimer Center. VU University Medical Center) ;
Gabel, Silvy (University Hospitals Leuven (Bèlgica)) ;
Meersmans, K. (University Hospitals Leuven (Bèlgica)) ;
Blin, Olivier (Clinical Pharmacology & Pharmacovigilance Department. Aix-Marseille University-CNRS) ;
Richardson, J. (Neurosciences Therapeutic Area. GlaxoSmithKline R&D) ;
De Roeck, Ellen E (University of Antwerp. Institute Born-Bunge) ;
Engelborghs, Sebastiaan (RUniversity of Antwerp. Institute Born-Bunge) ;
Sleegers, Kristel (Complex Genetics of Alzheimer's Disease Group. VIB Center for Molecular Neurology. VIB) ;
Bordet, Régis (Université de Lille. Department of Medical Pharmacology) ;
Rami Gonzalez, Lorena (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Kettunen, Petronella (University of Gothenburg) ;
Tsolaki, Magda (AHEPA University Hospital (Grècia)) ;
Verhey, F. R. J. (Maastricht University. Alzheimer Centrum Limburg) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Peyratout, Gwendoline (Lausanne University Hospital) ;
Tainta, Mikel (Fundación CITA-Alzhéimer Fundazioa) ;
Johannsen, Peter (Danish Dementia Research Centre. Rigshospitalet) ;
Freund-Levi, Yvonne (King's College London) ;
Frölich, L. (University of Heidelberg. Department of Geriatric Psychiatry) ;
Dobricic, Valerija (University of Lübeck. Institutes of Neurogenetics and Cardiogenetics) ;
Frisoni, Giovanni B. (IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli) ;
Molinuevo, José Luis (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Wallin, Anders (University of Gothenburg. Sahlgrenska Academy) ;
Popp, J. (University Hospital of Psychiatry Zürich) ;
Martinez-Lage, P. (Center for Research and Advanced Therapies. CITA-Alzheimer Foundation) ;
Bertram, Lars (University of Oslo. Department of Psychology) ;
Blennow, Kaj (Sahlgrenska University Hospital (Suècia)) ;
Zetterberg, Henrik (UCL Institute of Neurology (Regne Unit)) ;
Streffer, J. (Reference Center for Biological Markers of Dementia (BIODEM). Institute Born-Bunge. University of Antwerp) ;
Jelle Visser, P. (Maastricht University. Alzheimer Centrum Limburg) ;
Lovestone, Simon (Janssen-Cilag UK Ltd.) ;
Proitsi, P. (King's College London) ;
Legido-Quigley, Cristina (Steno Diabetes Center) ;
Universitat Autònoma de Barcelona
Background: physiological differences between males and females could contribute to the development of Alzheimer's Disease (AD). Here, we examined metabolic pathways that may lead to precision medicine initiatives. [...]
2021 - 10.3390/biomedicines9111610
Biomedicines, Vol. 9 Núm. 11 (november 2021) , p. 1610
|
|
|
3.
|
|
16 p, 2.1 MB |
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease
/
Visser, Pieter Jelle (Karolinska Institutet (Estocolm, Suècia)) ;
Reus, Lianne M. (Vrije Universiteit Amsterdam) ;
Gobom, Johan (Sahlgrenska Academy at the University of Gothenburg) ;
Jansen, Iris E (VU University) ;
Dicks, Ellen (Vrije Universiteit Amsterdam) ;
van der Lee, Sven J. (Vrije Universiteit Amsterdam) ;
Tsolaki, Magda (AHEPA University Hospital (Grècia)) ;
Verhey, Frans R. J. (Maastricht University) ;
Popp, Julius (University Hospital Zurich (Suïssa)) ;
Martinez-Lage, Pablo (Fundación CITA-Alzhéimer Fundazioa) ;
Vandenberghe, Rik (KU Leuven) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Molinuevo, José Luis (Hospital Clínic i Provincial de Barcelona) ;
Engelborghs, Sebastiaan (Vrije Universiteit Brussel) ;
Freund-Levi, Yvonne (Örebro University) ;
Froelich, Lutz (University of Heidelberg) ;
Sleegers, Kristel (University of Antwerp) ;
Dobricic, Valerija (University of Lübeck) ;
Lovestone, Simon (High Wycombe, UK) ;
Streffer, Johannes (AC Immune SA) ;
Vos, Stephanie J. B. (Maastricht University) ;
Bos, Isabelle (Maastricht University) ;
Smit, August B. (Vrije Universiteit Amsterdam) ;
Blennow, Kaj (Sahlgrenska Academy at the University of Gothenburg) ;
Scheltens, Philip (Vrije Universiteit Amsterdam) ;
Teunissen, Charlotte E. (Amsterdam University Medical Centers (AUMC)) ;
Bertram, Lars (University of Oslo) ;
Zetterberg, Henrik (Dementia Research Institute at UCL) ;
Tijms, Betty M. (Vrije Universiteit Amsterdam) ;
Universitat Autònoma de Barcelona
Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer's disease (AD) and is considered to result from neurodegeneration. T-tau levels, however, can be increased in very early disease stages, when neurodegeneration is limited, and can be normal in advanced disease stages. [...]
2022 - 10.1186/s13024-022-00521-3
Molecular neurodegeneration, Vol. 17 (march 2022)
|
|
|
4.
|
|
17 p, 1.3 MB |
Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics
/
Tijms, Betty M. (Vrije Universiteit Amsterdam) ;
Gobom, Johan (Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg) ;
Reus, Lianne (Vrije Universiteit Amsterdam) ;
Jansen, Iris E (Vrije Universiteit Amsterdam) ;
Hong, Shengjun (Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), Institutes of Neurogenetics and Cardiogenetics, University of Lübeck) ;
Dobricic, Valerija (Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), Institutes of Neurogenetics and Cardiogenetics, University of Lübeck) ;
Kilpert, Fabian (Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), Institutes of Neurogenetics and Cardiogenetics, University of Lübeck) ;
ten Kate, Mara (Vrije Universiteit Amsterdam) ;
Barkhof, Frederik (Institutes of Neurology and Healthcare Engineering, UCL London) ;
Tsolaki, Magda (AHEPA University Hospital (Grècia)) ;
Verhey, Frans R. J. (Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University) ;
Popp, Julius (Geneva University Hospitals (Suïssa)) ;
Martinez-Lage, Pablo (Fundación CITA-Alzhéimer Fundazioa) ;
Vandenberghe, Rik (Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Molinuevo, José Luis (Hospital Clínic i Provincial de Barcelona) ;
Engelborghs, Sebastiaan (Department of Neurology, UZ Brussel and Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB)) ;
Bertram, Lars (Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), Institutes of Neurogenetics and Cardiogenetics, University of Lübeck) ;
Lovestone, Simon (Janssen R&D) ;
Streffer, Johannes (UCB Biopharma SPRL) ;
Vos, Stephanie (Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University) ;
Bos, Isabelle (Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University) ;
Blennow, Kaj (Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg) ;
Scheltens, Philip (Vrije Universiteit Amsterdam) ;
Teunissen, Charlotte E. (Neurochemistry laboratory, Department of Clinical Chemistry, Amsterdam UMC - location VUmc, Amsterdam Neuroscience) ;
Zetterberg, Henrik (UCL Institute of Neurology (Regne Unit). UK Dementia Research Institute) ;
Visser, Pieter Jelle (Karolinska Institutet (Estocolm, Suècia). Department of Neurobiology, Care Sciences and Society) ;
Universitat Autònoma de Barcelona
Using CSF proteomics, Tijms et al. identify three Alzheimer's disease subtypes that show: 1) hyperplasticity and increased BACE1 levels; 2) innate immune activation; and 3) blood-brain barrier dysfunction with low BACE1 levels. [...]
2020 - 10.1093/brain/awaa325
Brain, Vol. 143 (november 2020) , p. 3776-3792
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
